Search clinical trials for: ZP4207(dasiglucagon) glucagon analogue

Total 30 results

Zealand Pharma

Completed

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Hypoglycemia | Diabetes Mellitus, Type 1

Canada, United States, Austria, Germany
Zealand Pharma

Completed

ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

Diabetes Mellitus Type 1

Germany
Zealand Pharma

Completed

Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

Hypoglycemia

United States, Germany, Slovenia
Zealand Pharma

Recruiting

A Study to Inv. Safety,Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children<6 Years With T1D

Hypoglycemia

United States
Zealand Pharma
SynteractHCR

Completed

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

Hypoglycemia | Diabetes Mellitus, Type 1

United States, Austria, Canada, Germany
Zealand Pharma

Completed

Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration

Hypoglycemia

Germany
Filip Krag Knop
Zealand Pharma

Active, not recruiting

Treatment of Post-bariatric Hypoglycaemia (SHERRY)

Hyperinsulinemic Hypoglycemia | Postprandial Hypoglycemia

Denmark
Zealand Pharma

Completed

Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon

Hypoglycemia

Germany
Zealand Pharma

Completed

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

Hypoglycemia | Diabetes Mellitus, Type 1

United States
University Hospital, Gentofte, Copenhagen

Completed

Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass

Hyperinsulinemic Hypoglycemia | Postprandial Hypoglycemia

Denmark
Zealand Pharma

Completed

A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Germany, Israel
Zealand Pharma

Active, not recruiting

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Germany, Israel
Zealand Pharma

Completed

A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM

Hypoglycemia | Diabetes Mellitus, Type 1

Canada
Zealand Pharma

Completed

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Israel, Germany
Zealand Pharma
Massachusetts General Hospital; Beta Bionics, Inc.

Completed

Feasibility Trial Testing the Bionic Pancreas With ZP4207 (dasiglucagon)

Diabetes Mellitus, Type 1

United States
Inreda Diabetic B.V.

Withdrawn

A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System (STABLE-1)

Diabetes Mellitus, Type 1

Netherlands
Insel Gruppe AG, University Hospital Bern

Withdrawn

Micro Glucagon During Exercise in Type 1 Diabetes

Hypoglycemia | Type 1 Diabetes

Switzerland
Zealand Pharma

Completed

Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator

Hypoglycemia

Germany
GlyPharma Therapeutics
VectivBio AG

Completed

Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support

Short Bowel Syndrome

Denmark
Mayo Clinic
National Center for Research Resources (NCRR); Rose Pharma A/S

Completed

Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients

Irritable Bowel Syndrome Constipation Predominant

United States
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd.

Completed

Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

Obesity

Australia
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd.

Completed

To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants (XW003)

Obesity | Type 2 Diabetes Mellitus | Nonalcoholic Steatohepatitis

Australia
Christina Kruuse

Recruiting

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke (EGRABIS1)

Ischemic Stroke

Denmark
Katarina Kos
University of Exeter

Terminated

Incretin and KATP Channels

Healthy Subjects

United Kingdom
Christina Kruuse

Completed

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers (EGRABINS1)

Stroke

Denmark
Athenex, Inc.

Completed

Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies

Advance Malignancies

United States
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM

Type 2 Diabetes Mellitus

China
University of Copenhagen
Bispebjerg Hospital

Not yet recruiting

Direct Versus Indirect Effect of Amino Acids on Hepatokines (Diaakine)

Obesity | Non-Alcoholic Fatty Liver Disease

Denmark
AstraZeneca

Not yet recruiting

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs (EXCEED)

Pancreatic Cancer
Spanish Breast Cancer Research Group
Eli Lilly and Company

Active, not recruiting

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (CARABELA)

Early Breast Cancer

Spain

3

Subscribe